IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

CHICAGO, IL—In experienced hands, compassionate use of the Pascal transcatheter valve repair system in patients with severe high-risk or inoperable tricuspid regurgitation (TR) can be safe and ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

The latest mitral valve repair and replacement devices were associated with favorable outcomes thus far, investigators reported. The Evoque, Tendyne, and Pascal devices are poised as potential ...

The Irvine, CA-based company said the Pascal repair system demonstrated high procedural success and significant clinical improvements in patients with challenging tricuspid anatomy and severe TR.

Edwards Lifesciences Corp. has gained a CE mark for its Pascal transcatheter valve repair system to treat tricuspid regurgitation (TR). It was previously approved for mitral regurgitation treatment.

Potentially fulfilling an unmet need among patients with mitral regurgitation (MR) who cannot be treated with MitraClip, the Pascal transcatheter mitral valve repair device can feasibly be implanted ...